Leerink reiterates Akebia stock rating on regulatory precedent By Investing.com

Leerink reiterated an Outperform rating on Akebia Therapeutics with a $3.00 price target, implying roughly 95% upside from the $1.54 share price. The firm says Travere’s Filspari approval in FSGS without nephrotic syndrome strengthens the regulatory case for Akebia’s praliciguat by validating proteinuria reduction as an approvable endpoint. Offset by recent mixed Q4 2025 results, including an EPS miss of -$0.05 versus $0.002 expected, the overall read is constructive for the pipeline but likely only modestly price-moving.

Analysis

This is less about one small biotech and more about a regulatory regime shift: if proteinuria is now being treated as a credible approvable surrogate, the value of nephrology pipelines with clean biomarker readouts rises materially while programs anchored to slower renal-function endpoints become relatively less attractive. That should re-rate the entire FSGS/IgA/lupus nephritis bucket, but the biggest beneficiary is likely the company with the most asymmetry between low current expectations and a binary catalyst window. The market is still discounting a high probability that this is just “supportive precedent” rather than a template the FDA will actually follow, which is why the move can persist longer than fundamentals would suggest.

The second-order effect is competitive: any sponsor with a proteinuria-heavy dataset now has a lower bar to argue for accelerated development, partnering leverage, or even financing on better terms. Conversely, names without a surrogate-driven path may face a higher implied cost of capital because investors will demand clearer clinical outcomes, not just biomarker noise. For AKBA specifically, the setup is attractive because the stock is cheap enough that even a modestly favorable read-through can produce convex upside, but that also means the downside is dominated by dilution risk if development timelines slip by even 6-12 months.

The main risk is that the market is extrapolating from a single approval into a broad FDA doctrine faster than regulators typically move. If the agency later narrows the interpretation to a specific population or insists on confirmatory evidence that is not easily portable across indications, the current enthusiasm can unwind quickly. Near term, the catalyst cadence looks months, not days: the trade should be expressed around protocol updates, end-of-phase discussions, and any partnering commentary rather than the headline itself.

Contrarian view: the better trade may not be the obvious long in the small-cap name, but the basket of nephrology developers that benefit from a higher probability of biomarker-based approval paths. If the thesis is right, the first-order move in AKBA could already be partly in the tape, while the broader repricing across the space is under-owned and less efficient. That argues for using AKBA as a tactical vehicle, not a core position, and taking profits into any sharp rerating rather than assuming the regulatory precedent compounds indefinitely.

Key Decisions for Investors

• Tactically long AKBA over the next 4-8 weeks into any regulatory follow-up or pipeline update; target a 2:1 upside/downside if the market starts pricing in a surrogate-endpoint approval path, but size small because dilution risk remains the main left-tail.
• Pair trade: long AKBA / short a slower-moving renal developer with less biomarker optionality over the next 1-3 months; thesis is relative rerating toward programs that can survive on proteinuria rather than hard renal decline endpoints.
• Buy AKBA call spreads 3-6 months out instead of common stock if liquidity allows; this captures binary upside from further regulatory validation while capping the risk of a financing-driven drawdown.
• Add a watchlist basket of nephrology names with proteinuria-driven readouts and re-underwrite their probability-weighted peak sales using a higher approval probability; the second-order rerating could be larger than the single-name move.
• If AKBA rallies sharply on follow-through commentary, trim 30-50% into strength; this is a catalyst trade, not a long-duration compounder, unless management can convert the regulatory read-through into partnership or data de-risking.